CSL Shares Back Into the Black YTD, Three Month Rally Hits 88%

CSL shares (ASX:CSL) has erased its losses for the year and returned to positive territory, completing one of the sharpest sentiment reversals on the Australian market in recent memory. The turnaround has been built on an earnings result that beat guidance, a drug-pricing agreement with the US government and a US$1.5 billion manufacturing expansion on American soil, not merely speculative froth.

The CSL share price has moved 1.1% higher year to date, a modest figure on its face but a dramatic improvement from the multi-year lows plumbed in early June. The stock has climbed about 40% over the past month and 88.48% over the past three months, with September opening with two consecutive sessions of gains.

The move has been helped along by broader sector sentiment, with the S&P/ASX 200 Health Care Index (XHJ) adding 17.91% over the past month as markets rotate back into defensive growth names.

Even so, the recovery remains only partly complete, with CSL still negative over a 12-month basis (-15.86%), and 42.79% lower over the past five years.

Driving the bounce in CSL shares

CSL’s drug-pricing agreement with the US Department of Health and Human Services has helped provide a boost for bulls. The company has committed to supplying medicines to Medicaid at prices comparable to those in other developed countries, and to applying similar most-favoured-nation (MFN) pricing principles to newly launched therapies across all US payers.

The White House named CSL among roughly nine international pharmaceutical and biotechnology companies to sign such deals, touting “tremendous discounts” for state Medicaid programs. Critically for markets, CSL has guided that it does not expect a material financial impact in FY27, framing the agreement as a source of policy and tariff certainty rather than a near-term earnings hit.

Then there is the US$1.5 billion expansion of CSL’s Kankakee, Illinois facility, which will bring end-to-end plasma processing to the United States and materially lift production of key immunoglobulin therapies Privigen and Hizentra. The new plant, expected to be operational around 2031, will deploy next-generation “Horizon 2” processes designed to extract more immunoglobulin from the same plasma base, improving both efficiency and output.

Perhaps the most important backstop was the FY26 result itself. Revenue of about US$15.8 billion and underlying net profit after tax of roughly US$2.6 billion came in well ahead of guidance, even as impairments and restructuring charges produced a statutory net loss of a similar magnitude.

Management has described FY26 as a “reset year” and signalled that FY27 will mark a return to growth as one-off charges wash through and investments in the Vifor integration and the plasma collection network begin to contribute. The contrast between strong underlying profit and a headline statutory loss keeps the earnings-quality debate alive, but the beat has clearly rebuilt management credibility with markets.

What Next?

On the calendar, CSL shares are scheduled to trade ex-dividend on 9 September, with a record date of 10 September, dates that may attract dividend-capture activity and add technical volatility around mid-September.

Having broken into positive territory YTD, the next major level to watch to the upside is at A$180, where the stock sat before the February drawdown.